
Novo Nordisk remains confident that obesity drug Wegovy will demonstrate positive cardiovascular benefits in people with obesity, according to the company’s executive vice president for development, Martin Holst Lange, speaking at a teleconference in connection with the company’s recently published financial report.
This assessment perhaps wasn’t a given considering that Novo Nordisk’s report laid out how the the external independent Data Monitoring Committee, DMC, had recommended the study continue as opposed to concluding early following a review of interim data back in July.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app